Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 4, 2010. The document serves as a correction to the company's unaudited preliminary results announcement for the fiscal year ended December 31, 2009, originally issued on February 4, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue totals, profit figures, cash flow, margins, debt, or liquidity metrics. It specifically addresses a correction to sales growth and turnover percentage data for "emerging markets."
- Emerging Markets Sales Growth (Corrected): 16% (previously reported as 28%).
- Emerging Markets Turnover Share (Corrected): 21% (previously reported as 24%).
Note: The "emerging markets" definition includes Pharmaceutical and Consumer Healthcare sales in GSK's Emerging Markets region plus Central and Eastern Europe and Asia Pacific markets, excluding Japan, Australia, and New Zealand.
Material Changes Versus Prior Period
The material change disclosed in this filing is a downward revision of the reported performance for emerging markets compared to the initial announcement. The sales growth figure was reduced by 12 percentage points, and the turnover share was reduced by 3 percentage points. The filing states that all other information within the original 2009 year-end announcement remains unchanged.
Guidance, Outlook, and Risks
This filing contains no new guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the correction of the statistical error regarding emerging market data.
Investor Verification Checklist
- Verify the corrected emerging markets sales growth of 16% and turnover share of 21% in the updated 2009 preliminary results.
- Confirm that the definition of "emerging markets" used aligns with the footnote provided (excluding Japan, Australia, and New Zealand).
- Review the original February 4, 2010 announcement to ensure no other data points were inadvertently affected by the correction.